Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tyra Biosciences, Inc. (Nasdaq: TYRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing precision medicines targeting FGFR biology through its in-house SNÅP platform. Its SEC filings give investors structured insight into how the company reports its financial condition, pipeline progress and material events related to its FGFR-focused programs.
Among the key documents, Form 8-K current reports are used by Tyra to announce material events such as quarterly financial results and significant clinical milestones. For example, recent 8-K filings reference press releases reporting second and third quarter financial results and an 8-K dated June 30, 2025 describing the first patient dosed in the SURF302 Phase 2 study of TYRA-300 (dabogratinib) in intermediate risk non-muscle invasive bladder cancer. These filings often incorporate press releases by reference, linking financial metrics with updates on studies like SURF302, BEACH301, SURF301, SURF201 and SURF431.
Investors can also use Tyra’s periodic reports (such as the annual report on Form 10-K and subsequent filings referenced in forward-looking statement sections) to understand risk factors, research and development priorities, and the status of clinical-stage candidates including dabogratinib, TYRA-200 and TYRA-430. The company’s filings discuss topics such as trial design, anticipated data readouts, dependence on third parties, regulatory interactions and intellectual property considerations.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain complex sections, highlight key disclosures and point out items of interest such as clinical trial milestones, cash runway commentary and forward-looking statements tied to the SNÅP platform and FGFR-targeted pipeline. Users can quickly review newly posted 8-Ks, 10-Ks and other forms, and connect them to Tyra’s broader narrative in precision oncology and genetically defined skeletal dysplasias.
Janus Henderson Group plc reported beneficial ownership of 2,856,290 shares of Tyra Biosciences common stock, equal to 5.4% of the class, in a Schedule 13G/A filing. The statement shows 0 shares of sole voting or dispositive power and 2,856,290 shares of shared voting and shared dispositive power, indicating the reported interest is held collectively by related entities. The filing identifies the reporting person type as IA, HC and lists indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios. A power of attorney authorizes named employees to prepare and file U.S. reporting forms on the group's behalf.
Tyra Biosciences, Inc. (TYRA) – Form 4 insider transaction
Director Gilla Kaplan filed a Form 4 disclosing two open-market sales of the company’s common stock.
- 06/17/2025: Sold 10 shares at $10.35 each.
- 06/18/2025: Sold 9,568 shares at a $9.7822 weighted-average price (individual trades ranged from $9.55 to $9.93).
After these transactions, Kaplan’s direct beneficial ownership stands at 28,231 shares. No derivative securities were involved, and the filing does not reference any 10b5-1 trading plan. The document was signed by Attorney-in-Fact Ali D. Fawaz on 06/20/2025.